Why the study?
T2MI occurs more frequently and carries worse outcomes than type 1 MI, but no clinical trial evidence is available to guide pharmacological therapies in this population.
Is it feasible to recruit patients with Type 2 myocardial infarction into a randomized trial of rivaroxaban versus placebo?
Is it feasible to recruit patients with Type 2 myocardial infarction into a randomized trial of rivaroxaban versus placebo?
Conducting clinical trials involving oral anticoagulation in patients with Type 2 myocardial infarction is highly challenging due to a very high rate of exclusion criteria.
Answers are grounded in this paper and cite their sources.
Recruitment failure halted the R2MI pilot; leaves open anticoagulation feasibility and efficacy questions in T2MI.
Background: Type 2 myocardial infarction (T2MI) occurs when myocardial oxygen demand exceeds myocardial oxygen supply. T2MIs occur more frequently and have worse outcomes compared to Type 1 myocardial infarction caused by an acute plaque rupture. No clinical trial evidence is available to guide pharmacological therapies in this high-risk population. Methods: The Rivaroxaban in Type 2 Myocardial Infarction (R2MI) trial (NCT04838808) was a trainee-led, pragmatic, pilot study that randomised patients with a T2MI to either rivaroxaban 2.5 mg twice daily or placebo. The trial was stopped early due to low recruitment. Investigators explored the challenges of conducting the trial in this population. This was supplemented by a retrospective chart review of 10,000 consecutive troponin assays undertaken during the study period. Results: Over a 1-year period, 276 patients with T2MI were screened for inclusion of which only 7 (2.5%) were randomised in the trial. Study investigators identified trial design and participant population factors that limited recruitment. These included: heterogeneity of patient presentation, poor clinical prognosis, and lack of dedicated non-trainee study personnel. The major limitation to recruitment was the frequency of identified exclusion criterion. The retrospective chart review identified 1715 patients with an elevated high-sensitivity troponin level, of which 916 (53%) were adjudicated to be related to T2MI. Of these, 94.5% possessed an exclusion criterion for the trial. Conclusion: Patients with a T2MI are challenging to recruit into clinical trials involving oral anticoagulation. Future studies should account for only ∼1 in every 20 screened individuals being a candidate for study recruitment.
No takes yet. Share an insight, caveat, or question.
Gouda et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: